Proof of concept in non-human primates of the heterologous prime-boost strategy combining dengue-2 virus and recombinant proteins including domain III of the viral envelope protein
Live attenuated viruses are the most advanced candidates against a dengue infection. They have been demonstrated to be immunogenic in preclinical and clinical studies. However, due to their replicative capacity, they require several doses to achieve the balanced immune response against the four sero...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elfos Scientiae
|
| Series: | Biotecnología Aplicada |
| Subjects: | |
| Online Access: | http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1027-28522013000200010&lng=en&tlng=en |
| _version_ | 1819052086290022400 |
|---|---|
| author | Iris Valdés Lisset Hermida Lázaro Gil Laura Lazo1 Gerardo Guillén María G Guzmán Jorge Castro Yaremis Romero Pedro Puente Jorge Martín Ernesto Marcos Carlos López Jorge Sánchez Olivia Niebla Tamara Menéndez Alienys Izquierdo Edith Suzarte José A Silva |
| author_facet | Iris Valdés Lisset Hermida Lázaro Gil Laura Lazo1 Gerardo Guillén María G Guzmán Jorge Castro Yaremis Romero Pedro Puente Jorge Martín Ernesto Marcos Carlos López Jorge Sánchez Olivia Niebla Tamara Menéndez Alienys Izquierdo Edith Suzarte José A Silva |
| author_sort | Iris Valdés |
| collection | DOAJ |
| description | Live attenuated viruses are the most advanced candidates against a dengue infection. They have been demonstrated to be immunogenic in preclinical and clinical studies. However, due to their replicative capacity, they require several doses to achieve the balanced immune response against the four serotypes. The use of a suitable combination using nonreplicative immunogens, without viral interference, can help to induce such a balanced response. This work dealt with the proof of concept of the heterologous prime-boost strategy combining in the same schedule in non-human primates of a live virus and the recombinant proteins containing the domain III of the viral envelope. These combinations may result in condensed immunization schedules for humans, thus reducing the number of doses with attenuated virus and the dose time spacing. In both studies, the humoral and cellular immune responses after the boost dose with each recombinant protein were evaluated. In the second study, additionally, the possibility of shortening the schedule was assessed, an advantage related with this prime-boost strategy. The boost effect was demonstrated by the neutralizing antibodies induced after recombinant protein immunizations. Additionally, it was confirmed that these neutralizing antibodies were long lasting, also the animals were able to mount a specific cellular immune response after the boost. This study won the Annual Award of the Academy of Sciences of Cuba in 2012. |
| first_indexed | 2024-12-21T12:14:14Z |
| format | Article |
| id | doaj.art-5d1a945a01924eba8dabba5d76f8d28d |
| institution | Directory Open Access Journal |
| issn | 1027-2852 |
| language | English |
| last_indexed | 2024-12-21T12:14:14Z |
| publisher | Elfos Scientiae |
| record_format | Article |
| series | Biotecnología Aplicada |
| spelling | doaj.art-5d1a945a01924eba8dabba5d76f8d28d2022-12-21T19:04:30ZengElfos ScientiaeBiotecnología Aplicada1027-2852302150152S1027-28522013000200010Proof of concept in non-human primates of the heterologous prime-boost strategy combining dengue-2 virus and recombinant proteins including domain III of the viral envelope proteinIris Valdés0Lisset Hermida1Lázaro Gil2Laura Lazo13Gerardo Guillén4María G Guzmán5Jorge Castro6Yaremis Romero7Pedro Puente8Jorge Martín9Ernesto Marcos10Carlos López11Jorge Sánchez12Olivia Niebla13Tamara Menéndez14Alienys Izquierdo15Edith Suzarte16José A Silva17Centro de Ingeniería Genética y BiotecnologíaCentro de Ingeniería Genética y BiotecnologíaCentro de Ingeniería Genética y BiotecnologíaCentro de Ingeniería Genética y BiotecnologíaCentro de Ingeniería Genética y BiotecnologíaInstituto de Medicina Tropical Pedro Kourí, IPKCentro de Ingeniería Genética y BiotecnologíaCentro de Ingeniería Genética y BiotecnologíaCentro de Ingeniería Genética y BiotecnologíaCentro de Ingeniería Genética y BiotecnologíaCentro de Ingeniería Genética y BiotecnologíaCentro de Ingeniería Genética y BiotecnologíaCentro de Ingeniería Genética y BiotecnologíaCentro de Ingeniería Genética y BiotecnologíaCentro de Ingeniería Genética y BiotecnologíaInstituto de Medicina Tropical Pedro Kourí, IPKCentro de Ingeniería Genética y BiotecnologíaCentro de Ingeniería Genética y BiotecnologíaLive attenuated viruses are the most advanced candidates against a dengue infection. They have been demonstrated to be immunogenic in preclinical and clinical studies. However, due to their replicative capacity, they require several doses to achieve the balanced immune response against the four serotypes. The use of a suitable combination using nonreplicative immunogens, without viral interference, can help to induce such a balanced response. This work dealt with the proof of concept of the heterologous prime-boost strategy combining in the same schedule in non-human primates of a live virus and the recombinant proteins containing the domain III of the viral envelope. These combinations may result in condensed immunization schedules for humans, thus reducing the number of doses with attenuated virus and the dose time spacing. In both studies, the humoral and cellular immune responses after the boost dose with each recombinant protein were evaluated. In the second study, additionally, the possibility of shortening the schedule was assessed, an advantage related with this prime-boost strategy. The boost effect was demonstrated by the neutralizing antibodies induced after recombinant protein immunizations. Additionally, it was confirmed that these neutralizing antibodies were long lasting, also the animals were able to mount a specific cellular immune response after the boost. This study won the Annual Award of the Academy of Sciences of Cuba in 2012.http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1027-28522013000200010&lng=en&tlng=endenguevaccine candidateprime-boostneutralizing antibodiesnon-human primates |
| spellingShingle | Iris Valdés Lisset Hermida Lázaro Gil Laura Lazo1 Gerardo Guillén María G Guzmán Jorge Castro Yaremis Romero Pedro Puente Jorge Martín Ernesto Marcos Carlos López Jorge Sánchez Olivia Niebla Tamara Menéndez Alienys Izquierdo Edith Suzarte José A Silva Proof of concept in non-human primates of the heterologous prime-boost strategy combining dengue-2 virus and recombinant proteins including domain III of the viral envelope protein Biotecnología Aplicada dengue vaccine candidate prime-boost neutralizing antibodies non-human primates |
| title | Proof of concept in non-human primates of the heterologous prime-boost strategy combining dengue-2 virus and recombinant proteins including domain III of the viral envelope protein |
| title_full | Proof of concept in non-human primates of the heterologous prime-boost strategy combining dengue-2 virus and recombinant proteins including domain III of the viral envelope protein |
| title_fullStr | Proof of concept in non-human primates of the heterologous prime-boost strategy combining dengue-2 virus and recombinant proteins including domain III of the viral envelope protein |
| title_full_unstemmed | Proof of concept in non-human primates of the heterologous prime-boost strategy combining dengue-2 virus and recombinant proteins including domain III of the viral envelope protein |
| title_short | Proof of concept in non-human primates of the heterologous prime-boost strategy combining dengue-2 virus and recombinant proteins including domain III of the viral envelope protein |
| title_sort | proof of concept in non human primates of the heterologous prime boost strategy combining dengue 2 virus and recombinant proteins including domain iii of the viral envelope protein |
| topic | dengue vaccine candidate prime-boost neutralizing antibodies non-human primates |
| url | http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1027-28522013000200010&lng=en&tlng=en |
| work_keys_str_mv | AT irisvaldes proofofconceptinnonhumanprimatesoftheheterologousprimebooststrategycombiningdengue2virusandrecombinantproteinsincludingdomainiiioftheviralenvelopeprotein AT lissethermida proofofconceptinnonhumanprimatesoftheheterologousprimebooststrategycombiningdengue2virusandrecombinantproteinsincludingdomainiiioftheviralenvelopeprotein AT lazarogil proofofconceptinnonhumanprimatesoftheheterologousprimebooststrategycombiningdengue2virusandrecombinantproteinsincludingdomainiiioftheviralenvelopeprotein AT lauralazo1 proofofconceptinnonhumanprimatesoftheheterologousprimebooststrategycombiningdengue2virusandrecombinantproteinsincludingdomainiiioftheviralenvelopeprotein AT gerardoguillen proofofconceptinnonhumanprimatesoftheheterologousprimebooststrategycombiningdengue2virusandrecombinantproteinsincludingdomainiiioftheviralenvelopeprotein AT mariagguzman proofofconceptinnonhumanprimatesoftheheterologousprimebooststrategycombiningdengue2virusandrecombinantproteinsincludingdomainiiioftheviralenvelopeprotein AT jorgecastro proofofconceptinnonhumanprimatesoftheheterologousprimebooststrategycombiningdengue2virusandrecombinantproteinsincludingdomainiiioftheviralenvelopeprotein AT yaremisromero proofofconceptinnonhumanprimatesoftheheterologousprimebooststrategycombiningdengue2virusandrecombinantproteinsincludingdomainiiioftheviralenvelopeprotein AT pedropuente proofofconceptinnonhumanprimatesoftheheterologousprimebooststrategycombiningdengue2virusandrecombinantproteinsincludingdomainiiioftheviralenvelopeprotein AT jorgemartin proofofconceptinnonhumanprimatesoftheheterologousprimebooststrategycombiningdengue2virusandrecombinantproteinsincludingdomainiiioftheviralenvelopeprotein AT ernestomarcos proofofconceptinnonhumanprimatesoftheheterologousprimebooststrategycombiningdengue2virusandrecombinantproteinsincludingdomainiiioftheviralenvelopeprotein AT carloslopez proofofconceptinnonhumanprimatesoftheheterologousprimebooststrategycombiningdengue2virusandrecombinantproteinsincludingdomainiiioftheviralenvelopeprotein AT jorgesanchez proofofconceptinnonhumanprimatesoftheheterologousprimebooststrategycombiningdengue2virusandrecombinantproteinsincludingdomainiiioftheviralenvelopeprotein AT olivianiebla proofofconceptinnonhumanprimatesoftheheterologousprimebooststrategycombiningdengue2virusandrecombinantproteinsincludingdomainiiioftheviralenvelopeprotein AT tamaramenendez proofofconceptinnonhumanprimatesoftheheterologousprimebooststrategycombiningdengue2virusandrecombinantproteinsincludingdomainiiioftheviralenvelopeprotein AT alienysizquierdo proofofconceptinnonhumanprimatesoftheheterologousprimebooststrategycombiningdengue2virusandrecombinantproteinsincludingdomainiiioftheviralenvelopeprotein AT edithsuzarte proofofconceptinnonhumanprimatesoftheheterologousprimebooststrategycombiningdengue2virusandrecombinantproteinsincludingdomainiiioftheviralenvelopeprotein AT joseasilva proofofconceptinnonhumanprimatesoftheheterologousprimebooststrategycombiningdengue2virusandrecombinantproteinsincludingdomainiiioftheviralenvelopeprotein |